EIF appointed Chief Executive
At the beginning of January 2023?Marjut Falkstedt will start as new Chief Executive of the European Investment Fund (EIF).
ADVERTISEMENT
About Maren Kühr
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 250 entries already.
Entries by Maren Kühr
Have biotech stocks bottomed out?
Biotechnology was dramatically rewarded in the financial markets through much of 2020 and the first half of 2021, widely credited for providing the COVID-19 vaccines. This followed four already exceptional years in the financial markets, with the Nasdaq Biotech Index (NBI) hitting its all-time high of 5449.32 on 30 August 2021.
Valneva: New created position
Valneva has appointed Dipal Patel as new Chief Commercial Officer and Management Board member.
Why we need the switch from oil to biotech now
Our species – modern humans, or homo sapiens sapiens – has ever striven for progress. And progress was greatly enabled by fire, a fundamental chemical phenomenon that allows the fast release of large amounts of energy.
Oxford Biomedica gains new CEO
Dr Frank Mathias, currently CEO at Rentschler Biopharma, will join Oxford Biomedica as CEO and Board Director in March 2023.
OxSonics Therapeutics with new Chief Executive Officer
At the beginning of november, OxSonics Therapeutics has appointed Jérôme Marzinski as its Chief Executive Officer.
AMR joint venture Aurobac appoints CEO
Aurobac Therapeutics has appointed Florence Séjourné as CEO. The French company is a joint venture, founded by Boehringer Ingelheim, Evotec and bioMérieux and focuses on combating antimicrobial resistance (AMR).
Bioxodes with management changes
Bioxodes SA,based in Marche-en-Famenne, Belgium, has appointed Marc Dechamps as its new CEO. Company founder, Edmond Godfroid, will take up the post of Chief Operations Officer (COO) alongside his existing responsibilities as Chief Scientific Officer (CSO).
MaaT Pharma appointed new CSO
French MaaT Pharma has appointed Nathalie Corvaïa as Chief Scientific Officer and will strengthens its R&D Activities in Immuno-Oncology.
Health: still a defensive position in portfolios?
Healthcare has long been considered one of the most reliable defensive sectors – an effective portfolio buffer when equity markets turn volatile. That’s because hospitals, drug makers, medical device firms and other companies across the healthcare sector benefit from steady consumer demand – still true?